Novavax Inc - Company Profile
Powered by
All the data and insights you need on Novavax Inc in one report.
- Save hours of research time and resources with
our up-to-date Novavax Inc Strategy Report
- Understand Novavax Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Novavax Inc (Novavax) is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune stimulating saponin-based adjuvants. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.
Novavax Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline | NanoFlu |
NVX-CoV2373 – Coronavirus | ResVax |
NanoFlu - Seasonal Influenza Vaccine | Matrix-M |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | In December, the company secured authorization from the Taiwan Food and Drug Administration for emergency use of Nuvaxovid XBB.1.5 dispersion for injection of COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older. |
2023 | Regulatory Approval | In November, the company secured expanded authorization from Health Canada for Nuvaxovid XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. |
2023 | Regulatory Approval | In October, the company received full marketing authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its prototype Covid-19 vaccine Nuvaxovid (NVX-CoV2373). |
Competitor Comparison
Key Parameters | Novavax Inc | Merck & Co Inc | Novartis AG | AstraZeneca Plc | GSK plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Switzerland | United Kingdom | United Kingdom |
City | Gaithersburg | Kenilworth | Basel | Cambridge | Brentford |
State/Province | Maryland | New Jersey | - | England | England |
No. of Employees | 1,543 | 72,000 | 76,057 | 89,900 | 70,212 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
James F. Young, Ph.D. | Chairman | Executive Board | 2011 | 70 |
John C. Jacobs | Chief Executive Officer; President; Director | Executive Board | 2023 | - |
Jim Kelly | Executive Vice President; Treasurer; Chief Financial Officer | Senior Management | 2021 | 57 |
John J. Trizzino | Chief Operating Officer; President | Senior Management | 2023 | 63 |
Rick Crowley | Executive Vice President; Chief Operating Officer | Senior Management | 2020 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer